~~<i id='04C5CE11A3'><strike id='04C5CE11A3'><tt id='04C5CE11A3'><pre id='04C5CE11A3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：leisure time 2025-09-02 17:49:31 - browse：4

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： AI for drug discovery: Experts on separating hype from reality

hotspot

entertainment

knowledge

focus

explore

leisure time

KentNishimura/GettyImagesYou’rereadingthewebversionofHealthCareInc.,STAT’sweeklynewsletterfollowingt

WSS

Former Pear Therapeutics executives start new VC firm

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

How to make over

Lawmakers grill UnitedHealth CEO on Change cyberattack

National associations that represent hospice owe an apology

DeSantis wants to import drugs. Biden’s FDA blasted his plan

knowledge

entertainment

hotspot

Activists slam private health insurers over coverage restrictions

Crowdfunding for medical bills sidesteps core problem, author says

State Dept. review finds Biden bears some blame for Afghanistan failures

As health system earnings go up, health insurance stocks go down

Hepatitis C has a cure — but many Americans still lack access to it

People can get long Covid without testing positive for virus: Study

Virginia high school admissions case could be legal follow

BIO to announce reorganization, senior leaders expected to depart

Heart attack and stroke risk calculators need revising

The effects of a landmark ruling on DNA ownership are becoming clearer

entertainment

How to make over

As obesity drug market grows, telehealth companies court payers

Intellia plays down concerns on accidental germline transmission

Wegovy improves function in certain heart failure patients

Former Pear Therapeutics executives start new VC firm

Abortion policy in the spotlight at Republican debate

knowledge

focus

explore

leisure time